person · Reporting owner
Washburn Theodore James Jr.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Principal Accounting Officer | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 868 |
Reported balance
After 2026-03-03 transaction · row 1
1 source rowRow 1 · 2026-03-03 · Sale · Disposed 5,272 · Balance 868 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2023 Filed Feb 14, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 273 | $28.44 | $7,764.12 |
DisclosureSEC source: 0001439222-23-000016 · wf-form4_167640875313872.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,172 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000026 · wf-form4_167658147701426.xml · derivative · entry 4 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 504 | $28.59 | $14,409.36 |
DisclosureSEC source: 0001439222-23-000026 · wf-form4_167658147701426.xml · nonDerivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,901 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 127 | $28.91 | $3,671.57 |
DisclosureSEC source: 0001439222-23-000026 · wf-form4_167658147701426.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,405 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:04 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000026 · wf-form4_167658147701426.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000016 · wf-form4_167640875313872.xml · derivative · entry 4 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777 Underlying: Common stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000016 · wf-form4_167640875313872.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 119 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 01, 2023 Filed Feb 14, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 6,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000016 · wf-form4_167640875313872.xml · derivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,896 Underlying: Common stock · 6,896 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 1, 2023. The shares underlying the restricted stock units will vest in full on February 1, 2025. F3 · derivative.expiration_date: The restricted stock units were granted on February 1, 2023. The shares underlying the restricted stock units will vest in full on February 1, 2025. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 1,165 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001439222-22-000028 · wf-form4_164634178943965.xml · derivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165 Underlying: Common stock · 1,165 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000028 · wf-form4_164634178943965.xml · derivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,331 Underlying: Common stock · 2,331 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:54 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 108 | $30.00 | $3,240.00 |
DisclosureSEC source: 0001439222-22-000025 · wf-form4_164617164759062.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,549 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 167 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000014 · wf-form4_164565050562951.xml · derivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 59 | $29.08 | $1,715.72 |
DisclosureSEC source: 0001439222-22-000014 · wf-form4_164565050562951.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,657 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 167 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000014 · wf-form4_164565050562951.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:56 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 233 | $30.81 | $7,178.73 |
DisclosureSEC source: 0001439222-22-000013 · wf-form4_164522134427957.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,549 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:00 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000009 · wf-form4_164504880629063.xml · derivative · entry 4 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360 Underlying: Common stock · 360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:00 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 504 | $31.25 | $15,750.00 |
DisclosureSEC source: 0001439222-22-000009 · wf-form4_164504880629063.xml · nonDerivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,782 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:00 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 127 | $30.50 | $3,873.50 |
DisclosureSEC source: 0001439222-22-000009 · wf-form4_164504880629063.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,286 Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:00 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000009 · wf-form4_164504880629063.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 34 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000007 · wf-form4_164487289859926.xml · derivative · entry 3 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,554 Underlying: Common stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 273 | $31.43 | $8,579.03 |
DisclosureSEC source: 0001439222-22-000007 · wf-form4_164487289859926.xml · nonDerivative · entry 2 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,019 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000007 · wf-form4_164487289859926.xml · nonDerivative · entry 1 Washburn Theodore James Jr. · CIK 0001874199 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.